CARM (CARISMA Therapeutics) Research & Development: $27.36 Mil (TTM As of Sep. 2025)


What is CARISMA Therapeutics Research & Development?

CARISMA Therapeutics CARM +1.25% Research & Development is $27.36 Mil as of Sep. 2025. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. CARISMA Therapeutics's Research & Development for the three months ended in Sep. 2025 was $0.20 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2025 was $27.36 Mil.

CARISMA Therapeutics  (OTCPK:CARM) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

CARISMA Therapeutics Research & Development Related Terms

CARISMA Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for CARISMA Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CARISMA Therapeutics Research & Development Chart

CARISMA Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
23.29 34.39 56.62 74.13 59.67

CARISMA Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.33 15.58 9.16 2.42 0.20

CARISMA Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $27.36 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $27.36 Mil mean?
CARISMA Therapeutics (CARM) has a Research & Development of $27.36 Mil as of Sep. 2025. Research and development expense is the total cost for research and development activities. View historical data on CARISMA Therapeutics and its competitors.
Is CARISMA Therapeutics' Research & Development too high?
CARISMA Therapeutics' current Research & Development is $27.36 Mil.
How does CARISMA Therapeutics' Research & Development compare to VRTX and REGN?
CARISMA Therapeutics' Research & Development of $27.36 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on CARISMA Therapeutics and its competitors. CARISMA Therapeutics's current Research & Development is $27.36 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CARISMA Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, CARISMA Therapeutics (CARM) is currently considered Possible Value Trap. The stock's GF Value™ is $3.71, compared to a current price of $0.01 — trading 99.8% below its estimated fair value. The current Research & Development is $27.36 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For CARISMA Therapeutics (CARM), the current Research & Development is $27.36 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CARISMA Therapeutics Business Description

Address 3675 Market Street, Suite 200, Philadelphia, PA, USA, 19104
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.